BGOG-ov85/TroFuse-021

A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy

Open

Trial drug

Sacituzumab Tirumotecan (sac-TMT)

Grade

High grade, Low grade, Other / unknown

Prior lines

Frontline

Histology

Serous, Mucinous Endometrioid Clear-cell

Phase

III

Treatment

This study consists of two different treatment options:

Arm 1: sac-TMT +/- bevacizumab
Arm 2: Standard of Care (Observation or bevacizumab)

The treatment is given as maintenance therapy following first-line platinum-based chemotherapy.

Treatment duration

Up to 18 cycles of sac-TMT maintenance therapy is allowed.

Contact

To be able to give you the best information and care we do not give medical advice via mail. We kindly ask you to make an appointment via lgog@uzleuven.be.